Depending on the sensitivity of the PCR used, clonally evolved CP could be the majority of frontline. It's not clear from the protocol what level of which mutations qualify are screened. I get your clarification on stage, but it's still misleading to leave the title as CP, and end points that refer to "time to accelerated phase" if they all start out AP.
News 
Market Data 
Discover 
